生物医药专刊

线粒体移植在心肌缺血损伤治疗中的研究

展开
  • ①福建医科大学附属协和医院,福建省心血管中心,福州 350001;②复旦大学 生物医学研究院,上海 200032

收稿日期: 2021-10-14

  网络出版日期: 2022-05-05

Advances of mitochondrial transplantation for myocardial ischemia

Expand
  • ①Heart Center of Fujian Province, Union Hospital, Fujian Medical University, Fuzhou 350001, China;②Institute of Biomedical
    Science, Fudan University, Shanghai 200032, China

Received date: 2021-10-14

  Online published: 2022-05-05

摘要

线粒体是为细胞提供能量的重要细胞器,调控细胞的正常生长和功能。许多疾病的发生都伴随着线粒体功能的异常。线粒体移植是一种潜在的可用于危重疾病的治疗方法,尤其是治疗缺血性疾病。文章从对心肌缺血损伤治疗的角度出发,简述线粒体移植的应用、作用机制及其局限性,为线粒体移植治疗的发展提供新的视角。

本文引用格式

陈航, 胡琴丰, 林丽, 刘建文, 陈康辉, 陈昭阳 . 线粒体移植在心肌缺血损伤治疗中的研究[J]. 自然杂志, 2022 , 44(2) : 109 -116 . DOI: 10.3969/j.issn.0253-9608.2022.02.005

Abstract

Mitochondria are important organelles that provide energy to cells and regulate cell signaling and growth. The development  of many diseases is accompanied by abnormal mitochondrial function. Mitochondrial transplantation is a potential therapy for critical  diseases, especially ischemic diseases. From the perspective of mitochondrial transplantation therapy for myocardial ischemia, this article briefly reviews the effectiveness, mechanism and limitations of mitochondrial transplantation aiming to shed new light on the development of mitochondrial transplantation therapy.
文章导航

/